Egen-initierede studier

  • Testing in coronary artery disease II - Laust Dupont Rasmussen
  • Betydning af social ulighed og utryghed for udvikling af kardiovaskulære og metaboliske risikofaktorer hos unge voksne – Mia Klinkvort Kempel
  • Management of patients with suspected stable coronary artery disease – Louise Bjerking
  • Coronary flow and plaque characteristics in kidney transplant candidates – Jonathan Nørtoft Dahl
  • Effect of including circulating proteins and genetic information in predictive risk models of obstructive coronary artery disease – Gitte Stokvad Brix
  • Opportunistisk screening for osteoporose – et dansk multicenter studie - Andia Cheneymann
  • Dan-NICAD 3 - Danish Study of non-invasive diagnostic testing in coronary artery disease III – Simon Winther
  • Association of subjective social status in adolescense and obesity in adulthood – a substudy from the VestLiv cohort - Louise Stampe
  • Association of physical activity in adolescense and cardio-metabolic-inflammatory risk markers in adulthood – a clinical substudy on sampled participants from the VestLiv Cohort - Stine Malling Søndergaard
  • Significance of socio-economic status, BMI, and sex in self-reported height and weight versus measured height and weight - a clinical substudy on sampled participants from the VestLiv Cohort – Vibeke Lynggaard
  • Optimal medicinsk behandling versus PCI for symptombyrde og perfusionsbedring malt på Rb-PET og Seattle Angina Questionnaire – a Dan-NICAD 2 substudy – Laust Dupont Rasmussen
  • Plaque analyses and comparisons within Dan-NICAD 1 + 2 – Laust Dupont Rasmussen og Jonathan Nørtoft Dahl

Nationale kardiologiske studier (ikke firmasponsorerede)

  • Dan-HEART – Hydralazine-ISDN and/or Metformin in Patients With Chronic Heart Failure and/or Diabetes or Insulin Resistance – A randomized, double-blind, placebo controlled study – coordinating site: AUH and Rigshospitalet
  • Dan-BLOCK – Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction – coordinating site: Bispebjerg and Frederiksberg Hospital
  • ARTESIA – Apixaban for the Reduction of Thrombo-Embolism in patients with device-detected Sub-clInical Atrial fibrillation – coordinating site: Population Health Research Institute, Hamilton, Canada

Clinical trials

  • OutcoMes by reducing triglycederides IN patiENts with diabeTes – sponsor: KOWA
  • AEGIS-II – A phase III, multicenter, Double-blind, Randomized, Placebo-controleld, Parallel-group Study to Investigate the Efficacy and safety of CSL112 (apolipoprotein A-I) in subject with Acute Coronary Syndrome – sponsor: CSL Behring LLC
  • SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity and established CV disease – sponsor: Novo Nordisk
  • ORION-8 – A long term extension trial of the phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL – sponsor: Novartis
  • VESALIUS – A double-blind, randomized, placebo-controlled, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial infarction or stroke – sponsor: Amgen
  • FINEARTS-HF – A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%) – sponsor: Bayer
  • SOLANO – A randomized, parallel, double-blind, placebo-controlled phase Iib study to assess the safety, tolerability and efficacy of AZD8233 (PCSK9-targeted ASO) treatment in participants with hyperlipidaemia – sponsor: AstraZeneca
  • ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systematic inflammation – sponsor: Novo Nordisk
  • SOS-AMI – Selatogrel Outcome Study in suspected Acute Myocardial Infarction – sponsor Idorsia
  • VICTORION-2-PREVENT – A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease – sponsor Novartis